Search Results - "M Mohty"

Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond by MOHTY, M

“…The success of allogeneic stem cell transplantation and solid-organ transplantation owes much to improvements in the immunosuppressive regimens that prevent…”
Get full text

Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remission by Ruggeri, A, Labopin, M, Ciceri, F, Mohty, M, Nagler, A

Get full text

Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report by Passweg, J R, Baldomero, H, Bader, P, Bonini, C, Duarte, R F, Dufour, C, Gennery, A, Kröger, N, Kuball, J, Lanza, F, Montoto, S, Nagler, A, Snowden, J A, Styczynski, J, Mohty, M

“…Hematopoietic stem cell transplantation (HSCT) is an established procedure for many acquired and congenital disorders of the hematopoietic system. A record…”
Get full text

Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually by Passweg, J R, Baldomero, H, Bader, P, Bonini, C, Cesaro, S, Dreger, P, Duarte, R F, Dufour, C, Kuball, J, Farge-Bancel, D, Gennery, A, Kröger, N, Lanza, F, Nagler, A, Sureda, A, Mohty, M

“…A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by…”
Get full text

Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT by Tsirigotis, P, Byrne, M, Schmid, C, Baron, F, Ciceri, F, Esteve, J, Gorin, N C, Giebel, S, Mohty, M, Savani, B N, Nagler, A

“…Allogeneic hematopoietic stem cell transplantation (allo-SCT) remains the therapeutic method with the most potent anti-leukemic activity mediated by the graft…”
Get full text

Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation by Corbacioglu, S, Carreras, E, Ansari, M, Balduzzi, A, Cesaro, S, Dalle, J-H, Dignan, F, Gibson, B, Guengoer, T, Gruhn, B, Lankester, A, Locatelli, F, Pagliuca, A, Peters, C, Richardson, P G, Schulz, A S, Sedlacek, P, Stein, J, Sykora, K-W, Toporski, J, Trigoso, E, Vetteranta, K, Wachowiak, J, Wallhult, E, Wynn, R, Yaniv, I, Yesilipek, A, Mohty, M, Bader, P

“…The advances in hematopoietic cell transplantation (HCT) over the last decade have led to a transplant-related mortality below 15%. Hepatic sinusoidal…”
Get full text

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation by Mohty, M, Malard, F, Abecassis, M, Aerts, E, Alaskar, A S, Aljurf, M, Arat, M, Bader, P, Baron, F, Bazarbachi, A, Blaise, D, Ciceri, F, Corbacioglu, S, Dalle, J-H, Dignan, F, Fukuda, T, Huynh, A, Masszi, T, Michallet, M, Nagler, A, NiChonghaile, M, Okamoto, S, Pagliuca, A, Peters, C, Petersen, F B, Richardson, P G, Ruutu, T, Savani, B N, Wallhult, E, Yakoub-Agha, I, Duarte, R F, Carreras, E

“…Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life threatening complication that can develop after…”
Get full text

Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey by Niederwieser, D, Baldomero, H, Szer, J, Gratwohl, M, Aljurf, M, Atsuta, Y, Bouzas, L F, Confer, D, Greinix, H, Horowitz, M, Iida, M, Lipton, J, Mohty, M, Novitzky, N, Nunez, J, Passweg, J, Pasquini, M C, Kodera, Y, Apperley, J, Seber, A, Gratwohl, A

“…Data on 68 146 hematopoietic stem cell transplants (HSCTs) (53% autologous and 47% allogeneic) gathered by 1566 teams from 77 countries and reported through…”
Get full text

Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT) by Mohty, M, Malard, F, Abecassis, M, Aerts, E, Alaskar, A S, Aljurf, M, Arat, M, Bader, P, Baron, F, Bazarbachi, A, Blaise, D, Ciceri, F, Corbacioglu, S, Dalle, J-H, Duarte, R F, Fukuda, T, Huynh, A, Masszi, T, Michallet, M, Nagler, A, NiChonghaile, M, Pagluica, T, Peters, C, Petersen, F B, Richardson, P G, Ruutu, T, Savani, B N, Wallhult, E, Yakoub-Agha, I, Carreras, E

“…Sinusoidal obstruction syndrome or veno-occlusive disease (SOS/VOD) is a potentially life-threatening complication of hematopoietic SCT (HSCT). This review…”
Get full text

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) by Hayden, P.J., Roddie, C., Bader, P., Basak, G.W., Bonig, H., Bonini, C., Chabannon, C., Ciceri, F., Corbacioglu, S., Ellard, R., Sanchez-Guijo, F., Jäger, U., Hildebrandt, M., Hudecek, M., Kersten, M.J., Köhl, U., Kuball, J., Mielke, S., Mohty, M., Murray, J., Nagler, A., Rees, J., Rioufol, C., Saccardi, R., Snowden, J.A., Styczynski, J., Subklewe, M., Thieblemont, C., Topp, M., Ispizua, Á.U., Chen, D., Vrhovac, R., Gribben, J.G., Kröger, N., Einsele, H., Yakoub-Agha, I.

“…Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for…”
Get full text

Hematopoietic stem cell transplantation in Europe 2014: more than 40000 transplants annually by Passweg, J.R, Baldomero, H, Bader, P, Bonini, C, Cesaro, S, Dreger, P, Duarte, R.F, Dufour, C, Kuball, J, Farge-Bancel, D, Gennery, A, Kroger, N, Lanza, F, Nagler, A, Sureda, A, Mohty, M

“…A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by…”
Get full text

Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update by Mohty, B, Mohty, M

“…Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for various malignant and non-malignant diseases. Many patients have now…”
Get full text

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Moreau, P, San Miguel, J, Ludwig, H, Schouten, H, Mohty, M, Dimopoulos, M, Dreyling, M

Get full text

Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants by Passweg, J R, Baldomero, H, Bader, P, Bonini, C, Cesaro, S, Dreger, P, Duarte, R F, Dufour, C, Falkenburg, J H F, Farge-Bancel, D, Gennery, A, Kröger, N, Lanza, F, Nagler, A, Sureda, A, Mohty, M

“…A record number of 39 209 HSCT in 34 809 patients (14 950 allogeneic (43%) and 19 859 autologous (57%)) were reported by 658 centers in 48 countries to the…”
Get full text

Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice by Ruutu, T, Gratwohl, A, de Witte, T, Afanasyev, B, Apperley, J, Bacigalupo, A, Dazzi, F, Dreger, P, Duarte, R, Finke, J, Garderet, L, Greinix, H, Holler, E, Kröger, N, Lawitschka, A, Mohty, M, Nagler, A, Passweg, J, Ringdén, O, Socié, G, Sierra, J, Sureda, A, Wiktor-Jedrzejczak, W, Madrigal, A, Niederwieser, D

“…GVHD remains the major impediment to broader application of allogeneic haematopoietic SCT. It can be prevented completely, but at the expense of other…”
Get full text

JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement by Snowden, J A, McGrath, E, Duarte, R F, Saccardi, R, Orchard, K, Worel, N, Kuball, J, Chabannon, C, Mohty, M

“…Blood and marrow transplantation (BMT) is a complex and evolving medical speciality that makes substantial demands on healthcare resources. To meet a…”
Get full text

Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015 by Sureda, A, Bader, P, Cesaro, S, Dreger, P, Duarte, R F, Dufour, C, Falkenburg, J H F, Farge-Bancel, D, Gennery, A, Kröger, N, Lanza, F, Marsh, J C, Nagler, A, Peters, C, Velardi, A, Mohty, M, Madrigal, A

“…This is the sixth special report that the European Society for Blood and Marrow Transplantation regularly publishes on the current practice and indications for…”
Get full text

Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia by Jethava, Y S, Sica, S, Savani, B, Socola, F, Jagasia, M, Mohty, M, Nagler, A, Bacigalupo, A

“…AML is currently the first indication for allogeneic hematopoietic stem cell transplantation (allo-HSCT), as shown by international transplant registries. The…”
Get full text

Inhibition of FLT3 in AML: a focus on sorafenib by Antar, A, Otrock, Z K, El-Cheikh, J, Kharfan-Dabaja, M A, Battipaglia, G, Mahfouz, R, Mohty, M, Bazarbachi, A

“…FMS-like tyrosine kinase 3 ( FLT3 ) is one of the most commonly mutated genes in AML. FLT3 is mutated in ~30% of patients with AML, either by internal tandem…”
Get full text

Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia by Ruggeri, A, Labopin, M, Sanz, G, Piemontese, S, Arcese, W, Bacigalupo, A, Blaise, D, Bosi, A, Huang, H, Karakasis, D, Koc, Y, Michallet, M, Picardi, A, Sanz, J, Santarone, S, Sengelov, H, Sierra, J, Vincent, L, Volt, F, Nagler, A, Gluckman, E, Ciceri, F, Rocha, V, Mohty, M

“…Outcomes after unmanipulated haploidentical stem cell transplantation (Haplo) and after unrelated cord blood transplantation (UCBT) are encouraging and have…”
Get full text